复方黄黛片诱导治疗急性早幼粒细胞白血病193例疗效分析  

Compound huangdai tablet as induction therapy for 193 patients with acute promyelocytic leukemia

作　　者：向阳[1] 王晓波[1] 孙淑君[1] 郭爱霞[1] 魏艾红[1] 成玉斌[1] 黄世林[1] 

机构地区：[1]解放军第210医院中医血液科,大连116021

出　　处：《中华血液学杂志》2009年第7期440-442,共3页Chinese Journal of Hematology

摘　　要：目的总结复方黄黛片诱导治疗193例急性早幼粒细胞白血病（APL）患者的疗效与不良反应。方法复方黄黛片1．25g，每日3次，饭后服；3d后逐渐增量至7．5g／d。结果193例患者均获完全缓解（CR），其中78．8％的患者在用药44．3（31～60）d后获CR；疗程中未出现严重的感染、出血，不诱发与加重DIC。治疗中的主要不良反应是胃肠道症状。110例患者治疗前后的丙氨酸转氨酶、尿素、肌酐、心电图的QTc间期等指标变化不大。结论复方黄黛片治疗APL具有CR率高，不抑制骨髓，不诱发与加重DIC，使用安全，患者耐受性好等特点。Objective To report the resuhs of curative and adverse effects of compound huangdai tablet （CHDT）as induction therapy for 193 patients with acute promyelocytic leukemia（APL）. Methods CHDT was administered 1.25 g orally three times a day after meal for three days, then the dosage was gradually increased to 7.5 g/d. Results One hundred and ninety-three patients achieved complete remission （CR） ,78.8% of whom in 30 to 60 days with an average time of 44.3 d. No serious infection, bleeding or DIC occurred during the treatment course. The major adverse effects were gastrointestinal symptoms. There was no change in lanine transaminase, urea, creatinine or electrocardiographic QTe interval in 110 APL patients observed before and after the treatment. Conclusion CHDT therapy is a modality of higher CR rate, good safety and tolerance without bone marrow suppression for APL patients.

关 键 词：复方黄黛片 白血病 早幼粒细胞 急性 治疗结果 药物毒性 

分 类 号：R686[医药卫生—骨科学]